Sells robotic systems, catheters and information systems for hospitals and physicians performing heart and other blood-vessel procedures.
10-K for FY2025, filed Mar 12, 2026Stereotaxis designs, manufactures and markets robotic systems, instruments and information systems for the interventional laboratory. Our…View ↗
Our primary clinical focus has been electrophysiology, specifically cardiac ablation procedures for the treatment of arrhythmias. Cardiac…View ↗
Our primary products include the Genesis RMN and the GenesisX RMN Systems, the Odyssey and Synchrony & SynX Solutions, various…View ↗
Most revenue comes from disposables, service and accessories; hospitals buy disposable devices for procedures and pay recurring service and software charges, with disposable sales tied to shipment or delivery. They also pay upfront for systems and installation, with system sales tied to acceptance of delivery or installation.
10-K for FY2025, filed Mar 12, 2026We promote our full suite of products necessary for a typical hospital implementation, subject to regulatory approvals or clearances. This…View ↗
Contracts related to the sale of systems typically contain separate obligations for the delivery of system(s), installation, and…View ↗
Revenue from sales of disposable products is recognized when control is transferred to the customers, which generally occurs at the time of…View ↗
10-K for FY2025, filed Mar 12, 2026
FY2025 revenue by product or service ↗$32.4M
10-K for FY2025, filed Mar 12, 2026
$32.4M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Systems
Sold outright
10-K for FY2025, filed Mar 12, 2026 |
32%
FY2022: 24%
|
Systems, FY2025
$10.2M Sources
|
Sold outright |
|
Disposables Service and Accessories
|
68%
FY2022: 76%
|
Disposables Service and Accessories, FY2025
$22.2M Sources
|
Hospitals purchase systems directly or through distributors; Stereotaxis also markets its products through sales agents, while third parties sometimes handle support as the customer's single point of contact.
10-K for FY2025, filed Mar 12, 2026We promote our full suite of products necessary for a typical hospital implementation, subject to regulatory approvals or clearances. This…View ↗
We provide worldwide maintenance and support services to our customers’ products directly or with the assistance of outsourced product and…View ↗
We market our products in the U.S and internationally through a direct sales force of senior sales specialists, distributors and sales…View ↗
No. It lost $21.6M in FY2025.
10-Q for Q3 FY2026, filed Nov 16, 2026
−$6.5MView ↗
10-Q for Q3 FY2026, filed Nov 16, 2026
Open tableView ↗
8-K, filed Nov 10, 2026
Adjusted operating expenses, excluding non-cash and one-time items, are expected to approximate $8 million per quarter going forward.…View ↗
8-K, filed Jul 9, 2026
On July 7, 2026, Stereotaxis, Inc. (the “Company”) completed its previously announced acquisition (the “Acquisition”) of shares and other…View ↗
Flat. Revenue was $32.4M in FY2025, about the same as the $35M of FY2021.
Expanded product range
The older report describes Genesis RMN and Odyssey as primary products and separately lists an integrated x-ray system; the latest lists GenesisX, Synchrony and SynX, and branded interventional devices including Map-iT, MAGiC and EMAGIN.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 12, 2026Our primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. We also offer to our customers the…View ↗
The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided…View ↗
The Odyssey Solution consolidates lab information onto one large integrated display, enabling physicians to view and control all the key…View ↗
The Stereotaxis Imaging Model S provides an integrated complete solution for a robotic interventional operating room. It is a single-plane…View ↗
Loading...